Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Recruiting

Phase 1

Phase 2

Autologous Stem Cell Transplant with Polatuzumab VedotinAutologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma

Sponsor:

New York Medical College

Code:

NCT04491370

Conditions

B-cell Lymphoma

Burkitt Lymphoma

Diffuse Large B Cell Lymphoma

Follicular Lymphoma

Mantle Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 12 - 70

Healthy Volunteers: Not accepted

Interventions

Polatuzumab vedotin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-29. This information was provided to ClinicalTrials.gov by New York Medical College on 2023-10-26.